From migraine to Parkinson’s and obesity, AbbVie is building dominant franchises across multiple high-growth areas. Read why ...

Pfizer's stock has seen a 7.5% bump, but the company's fundamentals tell a fuzzier story. Pfizer’s return on equity (ROE) is ...

Altria’s shrinking core business, strained cash flow, and failed smoke-free pivot threaten its dividend and valuation outlook. Find out why MO stock is a sell.